Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSDNASDAQ:EVAXNASDAQ:IKNANASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.87+2.1%$0.96$0.77▼$1.93$65.99M2.1372,426 shs79,541 shsEVAXEvaxion Biotech A/S$1.86-2.6%$2.97$1.70▼$22.05$2.18M-0.25592,496 shs58,519 shsIKNAIkena Oncology$1.39+0.7%$1.47$1.22▼$1.94$67.08M0.49196,723 shs33,176 shsPMVPPMV Pharmaceuticals$1.26+0.8%$1.40$1.20▼$2.26$65.44M1.45141,165 shs35,174 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical+2.14%+2.35%-20.17%-12.99%-46.95%EVAXEvaxion Biotech A/S-2.62%-4.12%-29.01%-68.74%-87.68%IKNAIkena Oncology+0.72%+2.96%-4.14%-16.27%0.00%PMVPPMV Pharmaceuticals+0.80%-8.03%-11.89%-20.25%-23.64%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSDClearside Biomedical2.2675 of 5 stars3.53.00.00.02.51.70.0EVAXEvaxion Biotech A/S1.6719 of 5 stars3.52.00.00.01.41.70.0IKNAIkena Oncology3.5197 of 5 stars3.35.00.00.03.41.71.3PMVPPMV Pharmaceuticals2.5226 of 5 stars3.62.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 3.00Buy$5.75560.84% UpsideEVAXEvaxion Biotech A/S 3.00Buy$20.00975.27% UpsideIKNAIkena Oncology 2.50Moderate Buy$3.00115.83% UpsidePMVPPMV Pharmaceuticals 3.20Buy$5.50336.51% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, IKNA, PMVP, and CLSD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/6/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/20/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/4/2025EVAXEvaxion Biotech A/SLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $6.002/3/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.0012/23/2024IKNAIkena OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$2.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$7.70M8.57N/AN/A($0.25) per share-3.48EVAXEvaxion Biotech A/S$3.30M0.66N/AN/A($5.83) per share-0.32IKNAIkena Oncology$659K101.79N/AN/A$3.52 per share0.39PMVPPMV PharmaceuticalsN/AN/AN/AN/A$4.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$32.49M-$0.45N/AN/AN/A-413.83%N/A-92.90%5/7/2025 (Estimated)EVAXEvaxion Biotech A/S-$22.12M-$1.45N/AN/AN/A-347.83%N/A-79.40%3/26/2025 (Estimated)IKNAIkena Oncology-$68.17M-$1.01N/AN/AN/AN/A-36.88%-33.08%5/12/2025 (Estimated)PMVPPMV Pharmaceuticals-$68.96M-$1.14N/AN/AN/AN/A-24.20%-21.67%5/8/2025 (Estimated)Latest EVAX, IKNA, PMVP, and CLSD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2025N/AEVAXEvaxion Biotech A/S-$0.26N/AN/AN/A$1.66 millionN/A3/11/2025Q4 2024IKNAIkena Oncology-$0.23-$0.18+$0.05-$0.19N/AN/A3/3/2025Q4 2024PMVPPMV Pharmaceuticals-$0.37-$0.45-$0.08-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A4.494.49EVAXEvaxion Biotech A/S7.991.002.80IKNAIkena OncologyN/A15.3215.32PMVPPMV PharmaceuticalsN/A13.9813.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%EVAXEvaxion Biotech A/S11.04%IKNAIkena Oncology75.00%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical9.20%EVAXEvaxion Biotech A/S41.64%IKNAIkena Oncology5.94%PMVPPMV Pharmaceuticals7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical3075.84 million68.87 millionOptionableEVAXEvaxion Biotech A/S601.17 million685,000No DataIKNAIkena Oncology7048.26 million45.39 millionNot OptionablePMVPPMV Pharmaceuticals5051.93 million47.81 millionOptionableEVAX, IKNA, PMVP, and CLSD HeadlinesRecent News About These CompaniesPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Acquired by BML Capital Management LLCMarch 8, 2025 | marketbeat.comHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals (NASDAQ:PMVP) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPSMarch 3, 2025 | marketbeat.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsMarch 3, 2025 | globenewswire.comPMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on ThursdayFebruary 27, 2025 | marketbeat.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Large Decline in Short InterestFebruary 13, 2025 | marketbeat.comPeapod Lane Capital LLC Buys New Shares in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)February 13, 2025 | marketbeat.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesFebruary 11, 2025 | globenewswire.comPMV Pharmaceuticals stock hits 52-week low at $1.32January 21, 2025 | msn.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 22, 2024 | markets.businessinsider.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)October 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialOctober 23, 2024 | finance.yahoo.comPMV provides update on Phase 2, Phase 1b portions of PYNNACLE trialOctober 23, 2024 | markets.businessinsider.comPMV Pharma (NASDAQ:PMVP) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comPenny Stocks To Buy With Just $1500: PMVP, BOLD, SPROSeptember 28, 2024 | msn.comPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells $10,827.00 in StockSeptember 13, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, IKNA, PMVP, and CLSD Company DescriptionsClearside Biomedical NASDAQ:CLSD$0.87 +0.02 (+2.14%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$0.89 +0.02 (+2.40%) As of 03/12/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Evaxion Biotech A/S NASDAQ:EVAX$1.86 -0.05 (-2.62%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$1.92 +0.06 (+3.28%) As of 03/12/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Ikena Oncology NASDAQ:IKNA$1.39 +0.01 (+0.72%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$1.39 0.00 (0.00%) As of 03/12/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.PMV Pharmaceuticals NASDAQ:PMVP$1.26 +0.01 (+0.80%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 03/12/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
